When Xaira Therapeutics debuted in 2024 with a gobsmacking $1 billion in funding, a natural expectation would have been for a ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Novartis is paying Abogen Biosciences $575 million upfront for an mRNA-encoded T-cell engager (TCE) that showed early clinical promise in autoimmune disease. The deal, which inclu ...
Adecto Pharmaceuticals’ 12-year story has come to an end as the immunotherapy biotech blamed a “risk-averse funding environment” for shutting up shop. | Adecto Pharmaceuticals’ 12-year story has come ...
The revelation of a patient death in Bristol Myers Squibb’s phase 3 trial of a potential pulmonary fibrosis treatment has ...
Roche Diagnostics has launched a new in vitro diagnostic test for newborn screening to detect a series of rare disorders. | Roche Diagnostics has launched a new in vitro diagnostic test for newborn ...
A more subdued volume of biopharma layoffs continued into the third quarter of 2026, validating predictions that the sector ...
As Foghorn digested the end of the Lilly partnership, the biotech said it was laying off 40% of its workforce, while “further ...
When recombinant DNA expert Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a ...
A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary ...
Sanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage im | Sanofi is paying Regeneron $1 billion ...
Eli Lilly has tied its amylin-Zepbound combination treatment eloraTZP to 23.3% average weight loss in patients struggling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results